Publications by authors named "Michael Urbich"

Claim this Profile
I
IPECAD Modeling Workshop 2023 Cross-Comparison Challenge on Cost-Effectiveness Models in Alzheimer's Disease.
Ron Handels, William L Herring, Farzam Kamgar, Sandar Aye, Ashley Tate, Michael Urbich

Value Health· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Proposal of a Cost-Effectiveness Modeling Approach for Heart Failure Treatment Assessment: Considering the Short- and Long-Term Impact of Hospitalization on Event Rates.
Gian Luca Di Tanna, Blake Angell, Michael Urbich, Peter Lindgren, Thomas A Gaziano

Pharmacoeconomics· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness Analysis of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease in Canada.
Jean Grégoire, Salimah Champsi, Manon Jobin, Laura Martinez, Michael Urbich

Adv Ther· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia.
Ahmed Alghamdi, Bander Balkhi, Abdulaziz Altowaijri, Nasser Al-Shehri, Lewis Ralph, Michael Urbich

Pharmacoecon Open· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health State Utilities of Patients with Heart Failure: A Systematic Literature Review.
Gian Luca Di Tanna, Michael Urbich, Heidi S Wirtz, Barbara Potrata, Marieke Heisen

Pharmacoeconomics· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014-2020).
Michael Urbich, Gary Globe, Krystallia Pantiri, Marieke Heisen, Craig Bennison

Pharmacoeconomics· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years.
Borislav Borissov, Michael Urbich, Boryana Georgieva, Svetoslav Tsenov, Guillermo Villa

J Mark Access Health Policy· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cost-utility of dabigatran etexilate compared with warfarin in treatment and extended anticoagulation of acute VTE in the UK.
Anamaria Vera Jugrin, Anastasia Ustyugova, Michael Urbich, Mark Lamotte, Tom Sunderland

Thromb Haemost· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of the PECARN rules in children with minor head trauma.
Daniel K Nishijima, Zhuo Yang, Michael Urbich, James F Holmes, Marike Zwienenberg-Lee

Ann Emerg Med· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis